UNCOVERED: 3 - The Untold Story

Victoria seals deal worth up to $350m for old CSL site

The Victorian government has purchased the former CSL site in Melbourne's inner north and on-sold part of the land to an animal vaccine giant.

AAP · Mar 1, 2024

Zoetis (ZTS): Analyzing Earnings for Potential Gains

Veterinary drugmaker Zoetis Inc. (ZTS) is all set to disclose its fiscal fourth-quarter earnings tomorrow. With the company boasting an impressive track record of consistently surpassing earnings expectations, would it be wise to acquire the shares of ZTS ahead of its earnings? Keep reading to find out….

StockNews.com · Feb 12, 2024

3 Buy-Rated Healthcare Dividend Stocks for Income Investors

Looking for analysts' favorite stock picks in a traditionally defensive sector, with solid dividend payments to help boost your returns? Here's a look at three stocks for income investors to consider at current levels.

Barchart · Nov 24, 2023

Here's How Much You Would Have Made Owning Zoetis Stock In The Last 5 Years

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 13.08% on an annualized basis producing an average annual return of 22.15%. Currently, Zoetis has a market capitalization of $79.88 billion.

Benzinga · Jul 5, 2022

Explained | Ancovax - India’s first COVID-19 vaccine for animals

The Centre has launched a COVID-19 vaccine for animals such as dogs, lions, leopards, mice and rabbits.

The Hindu · Jun 25, 2022

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,500 Today

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 11.89% on an annualized basis producing an average annual return of 20.56%. Currently, Zoetis has a market capitalization of $75.58 billion.

Benzinga · Jun 17, 2022

Here's How Much You Would Have Made Owning Zoetis Stock In The Last 5 Years

Zoetis (NYSE:ZTS) has outperformed the market over the past 5 years by 10.79% on an annualized basis producing an average annual return of 21.83%. Currently, Zoetis has a market capitalization of $79.47 billion.

Benzinga · Jun 3, 2022

Zoetis vs. IDEXX Laboratories: Which Animal-Health Services Stock is a Better Buy?

Rising pet ownership and an increasing focus on healthy livestock have boosted the demand for animal healthcare solutions. Therefore, animal healthcare service providers Zoetis (ZTS) and IDEXX Laboratories (IDXX) should benefit. But the stocks of which of these two companies is a better buy now? Read on to learn our…

StockNews.com · May 31, 2022

Zoetis Earnings Perspective: Return On Invested Capital

According to Benzinga Pro, during Q1, Zoetis (NYSE:ZTS) earned $594.00 million, a 43.83% increase from the preceding quarter. Zoetis also posted a total of $1.99 billion in sales, a 0.97% increase since Q4.

Benzinga · May 24, 2022

Zoetis: Q1 Earnings Insights

  Zoetis (NYSE:ZTS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Zoetis beat estimated earnings by 7.32%, reporting an EPS of $1.32 versus an estimate of $1.23.

Benzinga · May 5, 2022